This is the best returning share I've ever invested in. Looking forward to more for years to come.
Don't understand why the herd have missed this GEM.
One happy happy !
Shares look highly attractive on a risk/reward basis
Hemogenyx is capitalised at just under �15 million & looks to us to be one of the lowest valued biopharma development plays on the whole of the market with an EV of less than �13 million. Our very conservative DCF based analysis of the Conditioning Product alone suggests an initial target price of 18.15p, implying 332% upside. We therefore initiate coverage of Hemogenyx with a Conviction Buy stance.
Initial target price.